S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
66,000% upside on tiny biotech? (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 

Annexon (ANNX) Stock Forecast, Price & News

$2.81
-0.07 (-2.43%)
(As of 06/9/2023 ET)
Compare
Today's Range
$2.79
$3.06
50-Day Range
$2.10
$6.37
52-Week Range
$2.07
$7.65
Volume
567,169 shs
Average Volume
696,973 shs
Market Capitalization
$149.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.71

Annexon MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
423.6% Upside
$14.71 Price Target
Short Interest
Healthy
5.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.70mentions of Annexon in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$639,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

197th out of 987 stocks

Pharmaceutical Preparations Industry

87th out of 466 stocks


ANNX stock logo

About Annexon (NASDAQ:ANNX) Stock

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Receive ANNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter.

ANNX Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
ACCD, GSIT and ANNX are among after hour movers
Analyst Expectations for Annexon's Future
Why Shares of Annexon Are Plummeting Thursday
BTIG Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)
Analyst Ratings for Annexon
Annexon Biosciences (ANNX) Gets a Buy from H.C. Wainwright
See More Headlines

ANNX Price History

ANNX Company Calendar

Last Earnings
5/08/2023
Today
6/09/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANNX
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.71
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+423.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-141,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.85 per share

Miscellaneous

Free Float
42,940,000
Market Cap
$149.17 million
Optionable
Not Optionable
Beta
0.50

Key Executives

  • Mr. Douglas Love J.D.Mr. Douglas Love J.D. (Age 54)
    Esq., CEO, Pres & Director
    Comp: $830.99k
  • Dr. Larry C. Mattheakis Ph.D. (Age 65)
    Exec. VP & Chief Scientific Officer
    Comp: $296.45k
  • Dr. Ted Yednock Ph.D. (Age 64)
    Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
    Comp: $614.6k
  • Dr. Arnon Rosenthal Ph.D. (Age 66)
    Founder
  • Ms. Jennifer LewMs. Jennifer Lew (Age 49)
    Exec. VP & CFO
  • Miriam Mason
    Sr. VP of Corp. Communications
  • Mr. Michael Overdorf M.B.A. (Age 52)
    Exec. VP & Chief Bus. Officer
  • Henk-Andre Kroon M.D.
    Sr. VP of Translational Medicine
  • Mirella Villa Del Toro
    Sec.













ANNX Stock - Frequently Asked Questions

Should I buy or sell Annexon stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares.
View ANNX analyst ratings
or view top-rated stocks.

What is Annexon's stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month price objectives for Annexon's stock. Their ANNX share price forecasts range from $3.00 to $30.00. On average, they predict the company's share price to reach $14.71 in the next twelve months. This suggests a possible upside of 423.6% from the stock's current price.
View analysts price targets for ANNX
or view top-rated stocks among Wall Street analysts.

How have ANNX shares performed in 2023?

Annexon's stock was trading at $5.17 at the start of the year. Since then, ANNX shares have decreased by 45.6% and is now trading at $2.81.
View the best growth stocks for 2023 here
.

When is Annexon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ANNX earnings forecast
.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) EPS for the quarter, hitting analysts' consensus estimates of ($0.52).

What ETFs hold Annexon's stock?

ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN).

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE).

When did Annexon IPO?

(ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO.

What is Annexon's stock symbol?

Annexon trades on the NASDAQ under the ticker symbol "ANNX."

Who are Annexon's major shareholders?

Annexon's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (13.29%), GMT Capital Corp (2.65%), Acadian Asset Management LLC (1.52%), Simplify Asset Management Inc. (1.23%), Geode Capital Management LLC (0.73%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Bain Capital Life Sciences Fun, Bain Capital Life Sciences Inv, Douglas Love, James E Flynn, Jennifer Lew, Michael Overdorf, Muneer A Satter, Sanjay Keswani and Ted Yednock.
View institutional ownership trends
.

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annexon's stock price today?

One share of ANNX stock can currently be purchased for approximately $2.81.

How much money does Annexon make?

Annexon (NASDAQ:ANNX) has a market capitalization of $149.17 million. The company earns $-141,950,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How can I contact Annexon?

The official website for the company is www.annexonbio.com. The company can be reached via phone at 650-822-5500, via email at swheeler@wheelhouselsa.com, or via fax at 650-636-9773.

This page (NASDAQ:ANNX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -